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Dr Timothy Van Natta (Torrance, Calif). I can tell you as
a traumatologist this is very important work. It is true that the cohort
size is small, 27 patients, and the follow-up time with a median 31
days is relatively short, but to paraphrase Dr Miller from yesterday,
follow-up is short but still very valuable.
This work is important for 3 reasons. It is important because it is
informed, and what I mean by that is the Stanford group was at the
forefront of really tackling all kinds of thoracic aortic pathology
with endovascular means. Others then followed suit, but the Stan-
ford group was among the first to then bring to all of our attention
a lot of cautions, and I think that has implications with regard to
what you just talked about.
It is important because it is timely. There has been a virtual stam-
pede to use this endovascular technology for blunt aortic injuries
and other aortic pathology, and I think it is timely now that so
many groups are reporting this kind of work that we take a step
back and look at it critically and heed the cautions that you raise.
Finally, it is provocative. Of your 27 patients, 15 had a significant
pseudoaneurysm. That is 56%. I think we are kind of trained to look
at that and worry that the patient is a heartbeat away from a full rup-
ture and dying, yet you have shown, albeit in this small population,
that this may be the way to go. If you look at the American Asso-
ciation for the Surgery of Trauma report from last year looking at
how this is tackled across the country, 20% of the patients have
a significant procedure-related complication. So we should pay at-
tention to that.
I do have 3 questions for you. The first relates to imaging. You
stated that the imaging is all important as you work through your
algorithm and you rely on computed tomography angiography.
We and others use that to screen the patients, but then we rely
heavily on intravascular ultrasound (IVUS) to help characterize
whether this is just the tip of the iceberg when we see an intimal
injury or there is something more to it, and it helps with the seat-604 The Journal of Thoracic and Cardiovascular Surging of the endovascular device. You didn’t mention the use of
that. Do you use IVUS at all? If not, why not?
Dr Caffarelli. We do not use IVUS for characterization of the
initial injury pattern. Luckily, at Stanford our CT angio group is
very good with the quality of the images and the reformatted
data, so we have not used IVUS. We have used IVUS more with
the patients with aortic dissection and occasionally with stent
grafts. We do not use IVUS.
Dr Van Natta. My second question relates to the patient popu-
lation. It is a trauma patient population, notoriously difficult with
regard to follow-up. Do you think it is appropriate to nonopera-
tively manage a group of patients with a median follow-up of 31
days?
Dr Caffarelli. It really brings to the forefront 2 kinds of ap-
proaches, either a selective treatment approach, as our group is sug-
gesting, or treat all at once phenomenon, which other groups are
suggesting with the endovascular therapy. I think the follow-up
problem exists in both situations. We have thought about the
stent-graft technology and seen problems with it, especially in
this patient population, so we have opted to treat a little more crit-
ically. In our small cohort of patients, only 1 patient progressed to
operative therapy.
Dr Van Natta. Perhaps it is more important to follow the pa-
tients who have had the device placed than those who have not.
You changed what you did because you saw some problems with
the devices. As the devices evolved, you were limited because of
the small aorta and its small radius of curvature, but because there
are new devices, do you think your algorithm is going to change as
they become available?
Dr Caffarelli. I think our group is going to have to face that, es-
pecially with some of the newer devices (eg, the CTAG from WL
Gore and Associates, Inc, Newark, Del) coming on line with
a smaller size and improved conformability. I think it is going to
make our decision easier for the patients we do treat with TEVAR
technology, such as the neurologically injured patients who do not
tolerate permissive hypotension or some of the patients who have
had more significant injuries, such as a larger more complex pseu-
doaneurysm. The big concern we have is durability of the device.
We have only 10-year data as far as fatigue. In addition, what hap-
pens to the 20-year-old trauma patient with a 20-mm device who is
going to live to 50 years? We just don’t know the answer to that. I
don’t know if anyone else does.
Dr James Brown (Baltimore, Md). At R Adams Cowley Shock
Trauma, we have developed a robust experience in traumatic aortic
stent grafting spearheaded by Bart Griffith, our division chair. Con-
gratulations on a thoughtful presentation.
With new therapeutic options, decisions become more difficult:
what therapy for whom. I think the distillation of this could be ex-
tremely valuable, but if your report is read briefly, it may be ex-
tremely dangerous. Certainly what we have learned to fear are
the torn aortas with extensive mediastinal hematoma, and that bears
out in a couple of reports fromMaryland. Second, the way we have
gotten around the size discrepancy of available stent grafts in the
past is to use the abdominal cuff extenders, which are small enough
to match the aorta of young trauma patients. Would you comment
on whether you have tried this technique? Finally, in the end anal-
ysis, assuming that the next technologic leap will be made and the
right size stent graft is available to us for this repair technique, how
will the algorithm change? In the end, surgeons with the expertiseery c September 2010
Caffarelli et al Acquired Cardiovascular Diseaseneed to recommend to the world how this procedure should be per-
formed.
Dr Caffarelli. We have previously used the extender technique,
but not currently. We do have other device options becoming avail-
able. I think it may change things, but as of right now this is our pri-
mary treatment strategy for the patients without head trauma or more
significant injury, but we do have to follow these patients. I think the
shortcoming of the study is that we just don’t have that long-term fol-
low-up. It is in process, so we will just have to wait and see.
Dr Frank Baciewicz (Detroit, Mich). Does it make any differ-
ence in your initial decision whether to follow the patient or inter-
vene—if the patient shows up in your emergency department or if
he/she is transferred in from another institution? When patients areThe Journal of Thoracic and Catransferred to our center with this problem and they have been sta-
ble for a number of hours, we tend to watch them, whereas if they
just come in with the recent injury, we tend to take them to the op-
erating room more quickly.
Dr Caffarelli. The literature bears out that the biggest risk of
aortic rupture is going to be in the first 48 to 96 hours; that is
when the inflammatory process is the largest. Seventy percent
of our patients came from the outside; therefore, the interval
from injury to presentation at Stanford ranged from 1 day to
21/2 weeks; so, yes, it has a bearing on our treatment strategy.
The further patients are out from their injury, the more stable
we believe they are going to be, especially if we are able to con-
trol their blood pressures.rdiovascular Surgery c Volume 140, Number 3 605
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